Polybromo 1 (PBRM1), BRCA1 associated protein 1 (BAP1), and SET domain containing 2 (SETD2) have also been reported as potential therapeutic targets for ccRCC. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.